CD4 and lymphoma: This bias toward CD4 positivity in CAR-T cell dynamics should be kept in mind, as Mackall and Maus’s groups using CD19CAR-T cells to treat leukemia and lymphoma have detected the presence of CD4+ Tregs within the CAR-T cells products generated with viral vectors, and higher frequencies of Tregs are associated with poorer outcomes (45, 46).